<p>Twist Bioscience Corporation (NASDAQ:TWST - 获取免费报告) 的股价在周一的午盘交易中下跌了 4.4%，原因是内部人士出售股票。该公司的股价最低跌至 29.89 美元，最后交易价格为 29.82 美元。在午盘交易中，共成交 511,249 股，较平均交易量 1,276,625 股下降了 60%。该股票此前收盘价为 31.19 美元。</p>
<p>获取 <strong>Twist Bioscience</strong> 的提醒：</p>
<p>具体来说，首席财务官亚当·拉波尼斯（Adam Laponis）在 10 月 9 日（星期四）进行了一笔交易，出售了 2,517 股股票。这些股票的平均售价为 32.92 美元，总价值为 82,859.64 美元。交易完成后，首席财务官直接持有公司 91,525 股股票，价值约为 3,013,003 美元。这笔交易代表了他们持股比例的 2.68% 的减少。该出售在向美国证券交易委员会（SEC）提交的文件中披露，文件可通过 SEC 网站访问。此外，首席财务官亚当·拉波尼斯在 10 月 8 日（星期三）进行了一笔交易，出售了 3,000 股股票。这些股票的平均售价为 31.15 美元，总交易额为 93,450.00 美元。交易完成后，首席财务官直接持有公司 94,042 股股票，价值约为 2,929,408.30 美元。这笔交易代表了他们持股比例的 3.09% 的减少。该出售的披露信息可以在此找到。在其他 Twist Bioscience 的新闻中，内部人士丹尼斯·乔（Dennis Cho）在 10 月 6 日（星期一）进行了一笔交易，出售了 3,876 股股票。这些股票的平均售价为 32.19 美元，总价值为 124,768.44 美元。交易完成后，内部人士直接持有公司 98,710 股股票，价值约为 3,177,474.90 美元。这笔交易代表了他们持股比例的 3.78% 的减少。该出售在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。</p>
<h2>分析师评级升级与降级</h2>
<p>TWST 已经成为几份研究报告的主题。Evercore ISI 在 10 月 7 日（星期二）的研究报告中将 Twist Bioscience 的目标股价从 46.00 美元下调至 42.00 美元，并对该股票给予 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Twist Bioscience 的 “卖出（d-）” 评级。巴克莱在 10 月 2 日（星期四）的研究报告中将 Twist Bioscience 的目标股价从 45.00 美元下调至 40.00 美元，并对该股票给予 “增持” 的评级。最后，Cowen 在 8 月 4 日（星期一）的研究报告中重申了对 Twist Bioscience 的 “买入” 评级。九位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 48.50 美元。</p>
<p><strong>获取我们关于 Twist Bioscience 的最新研究报告</strong></p>
<h2>Twist Bioscience 价格表现</h2>
<p>该股票的市值为 18 亿美元，市盈率为-20.56，贝塔值为 2.38。该公司的 50 日简单移动平均线为 27.63 美元，200 日简单移动平均线为 32.53 美元。该公司的债务与股本比率为 0.03，速动比率为 3.60，流动比率为 3.90。</p>
<p>Twist Bioscience (NASDAQ:TWST - 获取免费报告) 最近于 8 月 4 日（星期一）发布了其财报。该公司报告季度每股收益（EPS）为-0.47 美元，超出分析师一致预期的-0.54 美元，超出幅度为 0.07 美元。Twist Bioscience 的净利润率为-23.51%，股本回报率为-29.03%。该公司季度收入为 9,606 万美元，而一致预期为 9,552 万美元。Twist Bioscience 已将其 2025 财年的指引设定为每股收益。2025 财年第四季度的指引为每股收益。研究分析师预计 Twist Bioscience Corporation 将在本年度发布-2.12 美元的每股收益。</p>
<h2>机构资金流入与流出</h2>
<p>机构投资者最近对该公司的持仓进行了调整。瑞银资产管理（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度将其在 Twist Bioscience 的持仓增加了 186.1%。瑞银资产管理现在持有该公司 2,442,262 股股票，价值 95,883,000 美元，此前在上一季度增持了 1,588,587 股。EdgePoint Investment Group Inc.在第二季度将其在 Twist Bioscience 的持仓增加了 114.3%。EdgePoint Investment Group Inc.现在持有该公司 2,385,942 股股票，价值 87,779,000 美元，此前在上一季度增持了 1,272,732 股。Nuveen LLC 在第一季度获得了 Twist Bioscience 的新股份，价值 31,960,000 美元。ARK 投资管理（ARK Investment Management LLC）在第一季度将其在 Twist Bioscience 的持仓增加了 11.5%。ARK 投资管理现在持有该公司 6,241,595 股股票，价值 245,045,000 美元，此前在上一季度增持了 645,730 股。最后，Balyasny 资产管理公司（Balyasny Asset Management L.P.）在第二季度将其在 Twist Bioscience 的持仓增加了 934.0%。Balyasny 资产管理公司现在持有该公司 628,241 股股票，价值 23,113,000 美元，此前在上一季度增持了 567,481 股。</p>
<h2>关于 Twist Bioscience</h2>
<p>（获取免费报告）</p>
<p>Twist Bioscience Corporation 从事合成 DNA 产品的制造和销售。该公司提供用于治疗、诊断、化学/材料、食品/农业、数据存储以及生物技术、制药、工业化学和农业公司以及学术实验室的各种应用的合成基因和基因片段；用于靶向 NGS、CRISPR 基因编辑、诱变实验、DNA 折纸、DNA 计算、DNA 数据存储等应用的寡核苷酸池；以及专注于药物发现和开发的客户所需的免疫球蛋白 G 蛋白。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Twist Bioscience</li>
<li>制造业股票投资</li>
<li>Absci 可能成为 AI 生物技术未来的两个理由，以及一个风险</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>Applied Digital 的空头头寸被挤压——接下来怎么办？</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>Levi Strauss 股票预计在 2026 年达到新高</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Twist Bioscience 吗？</h2>
<p>在你考虑 Twist Bioscience 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Twist Bioscience 并不在名单上。</p>
<p>虽然 Twist Bioscience 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TWST

<p>Twist Bioscience（纳斯达克代码：TWST）股价因内部人士抛售下跌 4.4%，至 29.82 美元，首席财务官 Adam Laponis 以 32.92 美元出售了 2,517 股，以 31.15 美元出售了 3,000 股。分析师已下调该股票评级，Evercore ISI 将其目标价从 46 美元下调至 42 美元。该股票市值为 18 亿美元，每股收益为-0.47。机构投资者增加了持股，瑞银资产管理公司将其持仓增加了 186.1%</p>

<p>Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report)'s stock price traded down 4.4% during mid-day trading on Monday following insider selling activity. The company traded as low as $29.89 and last traded at $29.82. 511,249 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 1,276,625 shares. The stock had previously closed at $31.19.</p>
<div class="lb-trans"><p>Twist Bioscience Corporation (NASDAQ:TWST - 获取免费报告) 的股价在周一的午盘交易中下跌了 4.4%，原因是内部人士出售股票。该公司的股价最低跌至 29.89 美元，最后交易价格为 29.82 美元。在午盘交易中，共成交 511,249 股，较平均交易量 1,276,625 股下降了 60%。该股票此前收盘价为 31.19 美元。</p>
</div><p>Get <strong>Twist Bioscience</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Twist Bioscience</strong> 的提醒：</p>
</div><p>Specifically, CFO Adam Laponis sold 2,517 shares of the stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $32.92, for a total value of $82,859.64. Following the completion of the transaction, the chief financial officer directly owned 91,525 shares of the company's stock, valued at approximately $3,013,003. This trade represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam Laponis sold 3,000 shares of the stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $31.15, for a total transaction of $93,450.00. Following the completion of the transaction, the chief financial officer directly owned 94,042 shares of the company's stock, valued at approximately $2,929,408.30. This trade represents a 3.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. In other Twist Bioscience news, insider Dennis Cho sold 3,876 shares of the stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $124,768.44. Following the completion of the transaction, the insider directly owned 98,710 shares of the company's stock, valued at approximately $3,177,474.90. This trade represents a 3.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>具体来说，首席财务官亚当·拉波尼斯（Adam Laponis）在 10 月 9 日（星期四）进行了一笔交易，出售了 2,517 股股票。这些股票的平均售价为 32.92 美元，总价值为 82,859.64 美元。交易完成后，首席财务官直接持有公司 91,525 股股票，价值约为 3,013,003 美元。这笔交易代表了他们持股比例的 2.68% 的减少。该出售在向美国证券交易委员会（SEC）提交的文件中披露，文件可通过 SEC 网站访问。此外，首席财务官亚当·拉波尼斯在 10 月 8 日（星期三）进行了一笔交易，出售了 3,000 股股票。这些股票的平均售价为 31.15 美元，总交易额为 93,450.00 美元。交易完成后，首席财务官直接持有公司 94,042 股股票，价值约为 2,929,408.30 美元。这笔交易代表了他们持股比例的 3.09% 的减少。该出售的披露信息可以在此找到。在其他 Twist Bioscience 的新闻中，内部人士丹尼斯·乔（Dennis Cho）在 10 月 6 日（星期一）进行了一笔交易，出售了 3,876 股股票。这些股票的平均售价为 32.19 美元，总价值为 124,768.44 美元。交易完成后，内部人士直接持有公司 98,710 股股票，价值约为 3,177,474.90 美元。这笔交易代表了他们持股比例的 3.78% 的减少。该出售在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>TWST has been the topic of several research reports. Evercore ISI lowered their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an &#34;outperform&#34; rating on the stock in a research report on Tuesday, October 7th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Twist Bioscience in a research report on Wednesday, October 8th. Barclays decreased their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an &#34;overweight&#34; rating on the stock in a research report on Thursday, October 2nd. Finally, Cowen restated a &#34;buy&#34; rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $48.50.</p>
<div class="lb-trans"><p>TWST 已经成为几份研究报告的主题。Evercore ISI 在 10 月 7 日（星期二）的研究报告中将 Twist Bioscience 的目标股价从 46.00 美元下调至 42.00 美元，并对该股票给予 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Twist Bioscience 的 “卖出（d-）” 评级。巴克莱在 10 月 2 日（星期四）的研究报告中将 Twist Bioscience 的目标股价从 45.00 美元下调至 40.00 美元，并对该股票给予 “增持” 的评级。最后，Cowen 在 8 月 4 日（星期一）的研究报告中重申了对 Twist Bioscience 的 “买入” 评级。九位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 48.50 美元。</p>
</div><p><strong>Get Our Latest Research Report on Twist Bioscience</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Twist Bioscience 的最新研究报告</strong></p>
</div><h2>Twist Bioscience Price Performance</h2>
<div class="lb-trans"><h2>Twist Bioscience 价格表现</h2>
</div><p>The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -20.56 and a beta of 2.38. The business's 50 day simple moving average is $27.63 and its 200-day simple moving average is $32.53. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90.</p>
<div class="lb-trans"><p>该股票的市值为 18 亿美元，市盈率为-20.56，贝塔值为 2.38。该公司的 50 日简单移动平均线为 27.63 美元，200 日简单移动平均线为 32.53 美元。该公司的债务与股本比率为 0.03，速动比率为 3.60，流动比率为 3.90。</p>
</div><p>Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.</p>
<div class="lb-trans"><p>Twist Bioscience (NASDAQ:TWST - 获取免费报告) 最近于 8 月 4 日（星期一）发布了其财报。该公司报告季度每股收益（EPS）为-0.47 美元，超出分析师一致预期的-0.54 美元，超出幅度为 0.07 美元。Twist Bioscience 的净利润率为-23.51%，股本回报率为-29.03%。该公司季度收入为 9,606 万美元，而一致预期为 9,552 万美元。Twist Bioscience 已将其 2025 财年的指引设定为每股收益。2025 财年第四季度的指引为每股收益。研究分析师预计 Twist Bioscience Corporation 将在本年度发布-2.12 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after acquiring an additional 1,588,587 shares in the last quarter. EdgePoint Investment Group Inc. lifted its stake in shares of Twist Bioscience by 114.3% in the second quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company's stock worth $87,779,000 after buying an additional 1,272,732 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Twist Bioscience in the first quarter worth $31,960,000. ARK Investment Management LLC raised its stake in Twist Bioscience by 11.5% during the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after purchasing an additional 645,730 shares during the last quarter. Finally, Balyasny Asset Management L.P. raised its stake in Twist Bioscience by 934.0% during the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company's stock valued at $23,113,000 after purchasing an additional 567,481 shares during the last quarter.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。瑞银资产管理（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度将其在 Twist Bioscience 的持仓增加了 186.1%。瑞银资产管理现在持有该公司 2,442,262 股股票，价值 95,883,000 美元，此前在上一季度增持了 1,588,587 股。EdgePoint Investment Group Inc.在第二季度将其在 Twist Bioscience 的持仓增加了 114.3%。EdgePoint Investment Group Inc.现在持有该公司 2,385,942 股股票，价值 87,779,000 美元，此前在上一季度增持了 1,272,732 股。Nuveen LLC 在第一季度获得了 Twist Bioscience 的新股份，价值 31,960,000 美元。ARK 投资管理（ARK Investment Management LLC）在第一季度将其在 Twist Bioscience 的持仓增加了 11.5%。ARK 投资管理现在持有该公司 6,241,595 股股票，价值 245,045,000 美元，此前在上一季度增持了 645,730 股。最后，Balyasny 资产管理公司（Balyasny Asset Management L.P.）在第二季度将其在 Twist Bioscience 的持仓增加了 934.0%。Balyasny 资产管理公司现在持有该公司 628,241 股股票，价值 23,113,000 美元，此前在上一季度增持了 567,481 股。</p>
</div><h2>About Twist Bioscience</h2>
<div class="lb-trans"><h2>关于 Twist Bioscience</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.</p>
<div class="lb-trans"><p>Twist Bioscience Corporation 从事合成 DNA 产品的制造和销售。该公司提供用于治疗、诊断、化学/材料、食品/农业、数据存储以及生物技术、制药、工业化学和农业公司以及学术实验室的各种应用的合成基因和基因片段；用于靶向 NGS、CRISPR 基因编辑、诱变实验、DNA 折纸、DNA 计算、DNA 数据存储等应用的寡核苷酸池；以及专注于药物发现和开发的客户所需的免疫球蛋白 G 蛋白。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Twist Bioscience</li>
<li>Manufacturing Stocks Investing</li>
<li>2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>Applied Digital’s Shorts Got Squeezed—Now What?</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Levi Strauss Stock Set to Reach New Highs in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Twist Bioscience</li>
<li>制造业股票投资</li>
<li>Absci 可能成为 AI 生物技术未来的两个理由，以及一个风险</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>Applied Digital 的空头头寸被挤压——接下来怎么办？</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>Levi Strauss 股票预计在 2026 年达到新高</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Twist Bioscience Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Twist Bioscience 吗？</h2>
</div><p>Before you consider Twist Bioscience, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Twist Bioscience 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Twist Bioscience 并不在名单上。</p>
</div><p>While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Twist Bioscience 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Twist Bioscience（NASDAQ:TWST）股价因内部人士出售股票下跌 4.4%